Gaps in Adherence to Guideline-Directed Medical Therapy Before Defibrillator Implantation.
作者信息
Fonarow Gregg C, Ziaeian Boback
机构信息
Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles Medical Center, Los Angeles, California.
Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, California.
出版信息
J Am Coll Cardiol. 2016 Mar 8;67(9):1070-1073. doi: 10.1016/j.jacc.2015.12.045.
Abstract
摘要
相似文献
1
Gaps in Adherence to Guideline-Directed Medical Therapy Before Defibrillator Implantation.
J Am Coll Cardiol. 2016 Mar 8;67(9):1070-1073. doi: 10.1016/j.jacc.2015.12.045.
2
Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation.
J Am Coll Cardiol. 2016 Mar 8;67(9):1062-1069. doi: 10.1016/j.jacc.2015.12.046.
3
Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008.
Am J Cardiol. 2014 Jun 15;113(12):2052-6. doi: 10.1016/j.amjcard.2014.03.049. Epub 2014 Apr 1.
4
Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications.
Am Heart J. 2012 Nov;164(5):750-755.e1. doi: 10.1016/j.ahj.2012.08.002. Epub 2012 Oct 16.
5
Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry.
Arch Intern Med. 2012 Jan 9;172(1):64-7. doi: 10.1001/archinternmed.2011.466. Epub 2011 Nov 14.
6
Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).
Heart Lung Circ. 2022 Nov;31(11):1531-1538. doi: 10.1016/j.hlc.2022.06.691. Epub 2022 Aug 20.
7
Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.
J Am Coll Cardiol. 2009 Feb 3;53(5):416-22. doi: 10.1016/j.jacc.2008.09.045.
8
Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
Circ Heart Fail. 2010 Sep;3(5):596-605. doi: 10.1161/CIRCHEARTFAILURE.109.912683. Epub 2010 Jul 15.
9
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
JAMA Cardiol. 2022 Feb 1;7(2):130-139. doi: 10.1001/jamacardio.2021.4585.
10
Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.
JACC Heart Fail. 2019 Oct;7(10):902-906. doi: 10.1016/j.jchf.2019.05.013. Epub 2019 Sep 11.
引用本文的文献
1
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis.
Int J Cardiovasc Imaging. 2025 Jun 5. doi: 10.1007/s10554-025-03436-4.
2
Evaluation of a Machine Learning-Guided Strategy for Elevated Lipoprotein(a) Screening in Health Systems.
Circ Genom Precis Med. 2025 Feb;18(1):e004632. doi: 10.1161/CIRCGEN.124.004632. Epub 2025 Jan 23.
3
Analysis of Physician Compliance with Guideline-Directed Medical Therapy for Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Study.
Rev Cardiovasc Med. 2023 Sep 18;24(9):257. doi: 10.31083/j.rcm2409257. eCollection 2023 Sep.
4
Team based collaborative care model, facilitated by mHealth enabled and trained nurses, for management of heart failure with reduced ejection fraction in India (TIME-HF): design and rationale of a parallel group, open label, multi-centric cluster randomised controlled trial.
Wellcome Open Res. 2023 Jul 12;8:197. doi: 10.12688/wellcomeopenres.19196.2. eCollection 2023.
5
The design of the Dashboard Activated Services and Telehealth for Heart Failure (DASH-HF) study: A pragmatic quality improvement randomized implementation trial for patients with heart failure with reduced ejection fraction.
Contemp Clin Trials. 2022 Sep;120:106895. doi: 10.1016/j.cct.2022.106895. Epub 2022 Aug 24.
6
Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department.
Egypt Heart J. 2020 Aug 24;72(1):53. doi: 10.1186/s43044-020-00088-8.
7
Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction.
Int J Cardiol Heart Vasc. 2018 Nov 8;22:1-5. doi: 10.1016/j.ijcha.2018.10.003. eCollection 2019 Mar.
本文引用的文献
1
Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation.
J Am Coll Cardiol. 2016 Mar 8;67(9):1062-1069. doi: 10.1016/j.jacc.2015.12.046.
2
Medication Adherence Based on Part D Claims for Patients With Heart Failure After Hospitalization (from the Atherosclerosis Risk in Communities Study).
Am J Cardiol. 2015 Aug 1;116(3):413-9. doi: 10.1016/j.amjcard.2015.04.058. Epub 2015 May 8.
3
Electronic medication packaging devices and medication adherence: a systematic review.
JAMA. 2014 Sep 24;312(12):1237-47. doi: 10.1001/jama.2014.10059.
4
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133. doi: 10.1016/j.jacc.2013.11.053. Epub 2014 Feb 5.
5
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.
6
Variation in medication adherence in heart failure.
JAMA Intern Med. 2013 Mar 25;173(6):468-70. doi: 10.1001/jamainternmed.2013.2509.
7
Medicare Part D enrollees' use of out-of-plan discounted generic drugs.
J Am Geriatr Soc. 2012 Feb;60(2):387-8. doi: 10.1111/j.1532-5415.2011.03812.x.
8
How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?".
Am J Cardiol. 2012 Mar 1;109(5):729-35. doi: 10.1016/j.amjcard.2011.10.033. Epub 2011 Dec 15.
9
Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry.
Arch Intern Med. 2012 Jan 9;172(1):64-7. doi: 10.1001/archinternmed.2011.466. Epub 2011 Nov 14.
10
Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study.
J Am Coll Cardiol. 2011 Sep 6;58(11):1112-8. doi: 10.1016/j.jacc.2011.05.033.
Zotero 插件